James C. Mullen is a notable figure in the biotechnology industry, known for his extensive experience in leadership roles. He was the CEO of Biogen, one of the largest biotechnology companies, from 2000 to 2010, guiding the organization during a...

James C. Mullen is a notable figure in the biotechnology industry, known for his extensive experience in leadership roles. He was the CEO of Biogen, one of the largest biotechnology companies, from 2000 to 2010, guiding the organization during a significant period of growth and development. After his time at Biogen, he served as CEO of Patheon until its acquisition by Thermo Fisher in 2017. More recently, Mullen took on the role of President and CEO at Editas Medicine in 2021. He brings a wealth of industry knowledge and expertise, especially in areas like drug development and manufacturing. Mullen holds a degree in Chemical Engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University, showcasing a solid foundation in both technical and business aspects of biotech. Beyond his corporate roles, he also contributes to the industry as a board member and chair for various organizations, helping to shape the future of biotechnology. His journey reflects a commitment to innovation and a deep understanding of the challenges and opportunities within the sector.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Editas Medicine CEOs

E

James C. Mullen

Ex-CEO of Editas Medicine

Education

N/A

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

February 1, 1958 - 67 years ago

CEO of Editas Medicine for

1 year 3 months (Feb 2021 - Jun 2022)

Previous Experience

CEO of Patheon N.V.; President and CEO of Biogen Inc.; various operating positions at Biogen.

Rivals

Competitors/colleagues of James C. Mullen

B

John Evans

CEO of Beam Therapeutics

2023 Compensation

Stock

$0.00

Salary

$685.00K

Bonus

$431.55K

Other

$17.68K

Total Holdings

$24.88M

Holdings

See how much did James C. Mullen make over time.

James C. Mullen's investment activity in Biogen has shown interesting trends over the years. By the end of 2022, his insider trading reflected values consistently around $6-8 million monthly prior to his tenure at Editas and showed a notable peak...

James C. Mullen's investment activity in Biogen has shown interesting trends over the years. By the end of 2022, his insider trading reflected values consistently around $6-8 million monthly prior to his tenure at Editas and showed a notable peak during late 2021, reaching almost $9.5 million in monthly values. This demonstrates the fluctuations in his investments, aligning with significant company events and performance metrics. Prior to that peak, his investments maintained strong numbers, often exceeding $6 million monthly throughout 2020 and into 2021. His trading patterns indicate an alignment with company performance and a strategic approach to managing his financial interests as a leader in the biotech space.

No data yet.

Insider Trading

See recent insider trades of James C. Mullen.

No insider trades found for this CEO.

Compensation History

See how much did James C. Mullen make over time.

In 2022, Mullen's total compensation was around $30.5 million, which included a base salary of about $154,000 and significant bonuses. This amount highlights the performance-based nature of his earnings, aligning with the company's financial goals and shareholder interests. Most of his compensation came from stock options and performance stock units, indicating a strategy to incentivize him based on the company's success. In the previous year, 2021, his total compensation was lower, at approximately $17.2 million. This substantial jump showcases how performance metrics directly tie into executive compensation in the biotech industry. Mullen's packages are structured to reward achievement in revenue and strategic goals, especially relevant in the competitive field of biotechnology.

Year

2022

Total Compensation

$487.94K

Salary

$153.85K

Board Justification

Biogen's compensation philosophy emphasizes pay-for-performance, aligning executive compensation with company performance and shareholder interests, while also considering market competitiveness.

Bonus

$315.62K

Board Justification

Prorated bonus for the period of employment in 2022, based on a target bonus of 150% of base salary and a Company Multiplier of 100%.

Other

$18.48K

Board Justification

Includes life insurance premiums and other benefits.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2022 as the focus is on stock options and performance-based awards.

Performance Metrics

Financial performance metrics included revenue and non-GAAP diluted EPS targets, as well as strategic goals related to Alzheimer's disease initiatives and pipeline development.

Other Editas Medicine CEOs

Here are other CEOs of Editas Medicine

Cynthia Collins

Ex-CEO of Editas Medicine

March 2019 - February 2021

Gilmore O’Neill

CEO of Editas Medicine

June 2022 - Present